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Fifty to eighty percent of Rett syndrome (RTT) cases have point mutations in the gene 
encoding methyl-CpG-binding protein-2 (MECP2).  A fraction of MECP2 negative classical 
RTT patients has large heterozygous deletions.  Robust Dosage PCR (RD-PCR) assays were 
developed as a rapid, convenient and accurate method to detect large heterozygous deletions 
and duplications.  A blinded analysis was performed for 65 RTT cases from Portugal by RD-
PCR in the coding exons 2-4 of the MECP2 gene.  Neither the patients with point mutations 
nor the non-classical RTT patients without point mutation had a deletion or duplication. 
One of remaining eight female patients with classical RTT without point mutation had a 
heterozygous deletion. This is the first report of a deletion spanning the entire MECP2 gene.  
The deletion was confirmed by southern blotting analysis and the deletion junction was 
localized 37kb upstream from exon 1 and 18kb downstream from exon 4.  No duplications 
were detected. Our results suggest that RD-PCR is an accurate and convenient molecular 
diagnostic method.  © 2005 Wiley-Liss, Inc. 
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INTRODUCTION 
Fifty to eighty percent of Rett syndrome (RTT; MIM# 312750) cases have point mutations in the MECP2 gene 
(Methyl-CpG-binding protein 2; MIM# 300005)(Amir et al., 1999; Miltenberger-Miltenyi., 2003).  Southern 
blotting analysis, quantitative PCR and MLPA (Multiplex Ligation-Dependent probe amplification) have been 
used to detect large deletions and duplications in the MECP2 gene of RTT patients without point mutation 
(Schollen et al., 2003; Erlandson et al., 2003; Ariani et al., 2004; Laccone et al., 2004).  In those reports, 12 out of 
59 (20.3%) classical RTT patients without point mutation have large deletions in MECP2 gene.  
Robust dosage PCR (RD-PCR) has been developed as a rapid, convenient and accurate method to detect 
heterozygous deletions and duplications (Liu et al., 2003).  The accuracy and consistency of RD-PCR has 
previously been validated in multiple blinded analyzes with 100% accuracy (Liu et al., 2003; Nguyen et al., 2004).  
RD-PCR has the advantages of rapid optimization and validation of new assays, and inclusion of positive controls 
without the requirement of the heterozygous deletion. The enhanced RD-PCR protocol has the additional 
advantages of tolerance toward genomic DNA of variable quality and uniform and unbiased performance across 
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regions of variable sequence context and GC content (Nguyen et al., 2004; Shi. et al., 2004).   
In our study, we used, for the first time, RD-PCR to detect heterozygous deletions in the MECP2 gene. A 
blinded analysis was performed for 65 RTT cases from Portugal.  One of eight patients with classical RTT without 
point mutation had a heterozygous deletion spanning the entire coding sequence.  The deletion was confirmed by 
southern blotting.  This is the first biological analysis report on RD-PCR. 
 
MATERIALS AND METHODS 
Samples 
The DNA was prepared from peripheral blood by Puregene DNA Isolation Kit (Gentra, Minneapolis, MN).  
The concentrations were measured by UV spectrophotometer at 260 nm and adjusted to a working concentration of 
30 ng/µl in TE buffer.  Forty-eight control samples were analyzed in a blinded validation analysis, in which gender 
was used as a surrogate for heterozygous deletions.   
Sixty-five RTT patient samples from Portugal and two blinded male controls were screened in the study.  
Patients were diagnosed according to the RTT diagnostic criteria defined by Hagberg et al (Hagberg et al., 1985 
and 2002), which includes psychomotor regression after a period of normal development, severe mental 
retardation, deceleration of head growth and loss of purposeful hand skills with appearance of stereotypical hand 
movements. 30 of the RTT samples were classical RTT patients, and 8 of these were negative MECP2 mutation 
according to our previous work.  
 
RD-PCR assay  
Genomic DNA samples were incubated at 90oC in TE buffer for 10 minutes to minimize RD-PCR bias (Shi et 
al., 2004). Four RD-PCR assays for the three coding exons of MECP2 gene were designed (Table 1) according to 
Liu et al (Liu et al., 2003), except for the 5' universal tail of 5' ggccaagtgt- 3'.  These assays were divided into two 
groups depending on whether the ATM or FUT gene was used as the autosomal control segment.  Group I had two 
assays in exon2 and exon3 of the MECP2 gene, exon 12 of the ataxia telangiectasia mutated (ATM) gene was the 
internal control.  Group II had the other two assays in the coding part of exon 4 of the MECP2 gene; the 
fucosyltransferase 2 (FUT) gene was the internal control.  
Ten more RD-PCR assays were developed in the 3’ and 5’ flanking regions of the MECP2 gene to localize the 
deletion junction.  The primers were designed according to the genomic sequence from NT_025965 (GenBank 
accession number) (data not shown).  
The PCR mixtures contained a total volume of 25µl: 1xExpand™ High Fidelity buffer#3 (Roche), 4.5 mM 
MgCl2, 200 µM of each dNTP for Group I or 3.0 mM MgCl2 and 150 µM dGTP/50 µM deaza-dGTP, 200 µM of 
each other dNTPs and 10% DMSO for Group II, 0.1-0.2 µM of each pair of primers, 1U Platinum Taq DNA 
polymerase (Invitrogen) and 1U platinum Taq DNA polymerase High Fidelity (Invitrogen), 0.5 µg of BSA, and 60 
ng of genomic DNA.  The cycling entailed denaturation at 94oC for 15 sec, annealing at 55oC for Group I or 65oC 
for Group II for 30 sec, and elongation at 72oC for 1 min for 23 cycles. 
 
Quantitation 
Twelve µl of PCR product was electrophoresed through a standard 2% agarose gel.  Gels were stained in 
0.2µg/ml Ethidium Bromide for 1 hour and scanned by Typhoon 9410 Imager (Amersham) with the following 
parameters: focal plane =+3 mm, laser wavelength= 532 nm, Green, emission filter =610 BP 30, photomultiplier 
voltage =600 V, pixel size =100µm and sensitivity =normal.  
ImageQuant™ software was used to quantitate the PCR yield.  Net signal of a product band was obtained by 
subtracting local background signal from total signal in arbitrary unit.  The ratio of yields (ROY) is calculated by 
dividing the target net signal by the internal control net signal.  For normalization, the ROY of the patient sample 
was divided by the average ROY of the normal females. 
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Table 1. List of Primer Pairs and PCR Segments 
 
                        3' sequence-specific region                                                        Core PCR segmentc  
           Namea              Sequenceb (5'-3')   T GC%    Region      Size Tm GC% m   
                                          (oC)                        (oC) 
Assay 1 
Target  
MECP2-2(709463)D     5'TTTAGTCTTTGGGGTACTTTTA3'    45.4  32      Exon 2 of MECP2     492    74.1    38 
MECP2-2(709954)U     5'GGCTTGTGATAGTGTTGATTCT3'    47.8  41  
 
Controld  
ATM(38415)D       5'ATCCTGCAAGTTTACCTAAC3'         44.9  41      Exon 12 of ATM       418    75.2     41 
ATM(38829)U             5'GATCAGGGATATGTGAGTGT3'       46.4  43  
    
Assay 2  
Target   
MECP2-3(649492)D     5'ACCTGGTCTCAGTGTTCATTGT3'   50.0  46     Exon 3 of MECP2     486    81.2     55 
MECP2-3(649977)U     5'CTTCAGGGAAGAAAAGTCAGAA3'   49.8  41  
 
Assay 3  
Target  
MECP2-4-1(647695)D   5'CTTTGTCAGAGCCCTACCCATA3'   52.7  50      Exon 4-1 of MECP2   447    83.5   61 
MECP2-4-1(648141)U   5'CCACCATCACCACCACTCAGAG3'     56.5  59     
 
Control  
FUT(502)D                     5'TTCACCGGCTACCCCTGCTC3'      58.6  65       FUT2                      504    83.5    61 
FUT(1006)U                   5'GGAGTCGGGGAGGGTGTAAT3'      54.1  60   
 
Assay 4  
Target   
MECP2-4-2(648547)D   5'CCCCCTGGCGAAGTTTGAAAAG3' 60.5  55      Exon 4-2 of MECP2   400    81.2   56 
MECP2-4-2(648946)U   5'CCACCATCCGCTCTGCCCTATC3'   61.4  64    
 
    G
roup I                                          G
roup II 
a. For example, MECP2-2(709463)D: MECP2=methyl CpG binding protein 2, Xq28, its sequence is from NT_025965.13 
(GenBank accession number); 5’ end of the 3’ sequence-specific region of the primer begins at 709463; and D, downstream. 
The precise sizes and locations of the PCR fragment can be obtained from the information names. ATM=ataxia telangiectasia 
mutated, 11q22-q23, its sequence is from U82828; FUT=fucosyltransferase 2,19q13, its sequence is from D82933. 
b. The sequence of the 3' sequence-specific region is shown. A 10-nucleotide universal tail (5' ggccaagtgt 3') is attached to 
the 5' end of each primer. Note that the control primers have been redesigned relative to previous report  (Liu et al., 2003) to 
incorporate the 10-nucleotide universal tail. 
c. The core PCR segment does not include the tails. 
d. Exon 12 of ATM gene and FUT gene were internal controls of the Group I and Group II. They are listed in one assay in 
each group and left out in others.  
 
Southern blotting analysis 
Southern blot was performed using probes RTT2 (709610-709766, sequence is from NT_025965.13), RTT3 
(649518-650043) and p(A)10 (639141-639564) that hybridized with exon 2, exon 3 and the end of the 3’UTR. 
Probes were generated by PCR from genomic DNA, purified from 1% agarose gel by QIAEX II (QIAGEN, 
Valencia, CA) and labeled with 32P dCTP by Prime-It II Random primer (Stratagene, Cedar Creek, TX). The 
genomic DNA (8µg) of female control, male control and patient P3 was digested with Hind III and Pst I for probe 
RTT2, Sac I for probe RTT3 and Hind III and Sac I for probe p(A)10. Digested DNA fragments were separated in 
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a 1.5% agarose gel and blotted into a nylon membrane (Hybond H-N+; Amersham Pharmacia Biotech, 
Buckinghamshire, England). Hybridization was performed overnight at 65ºC and washings were carried out in a 
series of SSC/SDS solutions (0.1%SDS, 2%-0.1% SSC). Membranes were exposed to storage phosphor screen, 
scanned by Typhoon 9410 Imager  (Amersham, Molecular Dynamics, Sunnyvale, CA). ImageQuant™ software 
was used to quantitate the signals. 
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Figure 1. Schematic representation of the MECP2 gene regions analysed by Southern blotting and localization of the probes 
used in the assay (figure is not to scale). 
 
RESULTS AND DISCUSSION 
Validation by blinded analysis with 100% accuracy 
RD-PCR, a duplex PCR, amplifies an endogenous internal control and a target locus.  The internal control has a 
known gene copy number per cell while the target has an unknown number per cell.  The ROY was directly 
proportional to the ratio of the two input templates, so the copy number of the MECP2 gene could be obtained 
according to the ROY and the known copy number of the internal control.  
For validation of the four assays in the MECP2 gene, a blinded analysis was performed with 48 blinded 
genomic DNA samples where either the sex status or the number of each status were unknown (Fig. 2A).  The 
male sample was functionally equivalent to a RTT patient with large heterozygous deletion.  All the males and 
females were determined with 100% accuracy.  The standard deviations of ROY were around 0.04 in both male 
and female samples in each of the assay.  
 
Large heterozygous deletion found in one patient 
Exons 2, 3 and 4 of the MECP2 gene were analyzed for deletions by four RD-PCR assays.  ROYs of each assay 
were obtained and the copy numbers of the three coding exons 2-4 of the MECP2 gene were determined in the 65 
patient samples and two blinded male controls (Fig. 2B).  All the 65 patient samples were previously scanned for 
point mutation in coding exons and immediate flanking intronic regions of MECP2 gene by DOVAM-S (Detection 
of virtually all mutations-SSCP).  The RD-PCR analysis was performed blinded to previous point mutation 
scanning.  Only one of eight female patients with classical RTT without point mutation (P3) and two blinded male 
controls, P1 and P2 showed much lower ROY values than all the other female patients in all the four assays.  
ROYs of the female patient P3 were 0.44, 0.49, 0.51, and 0.52, indicating that the patient carried a large 
heterozygous deletion spanning the completely coding region of the MECP2 gene.  None of  22 patients with non-
classical RTT with point mutations had a heterozygous deletion.  No patient with duplication was observed.  
Except for the three samples, P1, P2 and P3, the means and standard deviations of the ROYs were 1.00±.0.09, 
1.02±0.08, 1.00±0.09 and 1.00±0.10 respectively; the ranges of ROYs were 0.83-1.22 for Assay 1, 0.83-1.21 for 
Assay 2, 0.83-1.21 for Assay 3 and 0.79-1.22 for Assay 4.  The two blinded male controls were both detected as 
heterozygous deletions in every assay.  All female patients without deletions or duplications had ROYs clearly 
distinguishable from the male controls and the patient with deletion.  These strongly supported the accuracy of the 
RD-PCR assays. 
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Southern blotting analysis was used to confirm the deletion identified by RD-PCR method.  Signal intensity of 
patient P3 was similar to that of the male control with probes RTT2, RTT3 and p(A)10 (Fig. 3), indicating only 





Figure 2. Analysis of copy number of the coding region of the MECP2 gene. A: Blinded RD-PCR analysis for exon2.  Lanes 1 
to 10 are blinded normal control samples, where the gender is unknown.  F is a normal female control, M is a normal male 
control, N is a negative control without DNA added.  D is PhiX174 DNA/Hae III Markers, in which three bands of 603bp, 
310bp, 281bp+217bp were shown. The ROY of each sample is indicated.  B: ROY for four RD-PCR assays. Sixty-seven 
samples were tested for each assay.  Y-axis is ROY, crossed with X-axis at 1.0. P1, P2, and P3 have much lower ROYs, 
indicating only one copy of the MECP2 gene.  P3 is the RTT patient with the deletion; P1 and P2 are male controls. 
 
Characterization of the large deletion in the female patient P3 
To localize the deletion junction, ten more RD-PCR assays were developed flanking the MECP2 gene.  The 
deletion junction was located within a region of 37.2kb upstream from 5’ end of exon 1 and 18.1kb downstream 
from 3’ end of exon 4 (Fig. 4).  Long-distance PCR approaches were designed, but unfortunately failed, probably 
because the DNA was partially degraded. 
 











Figure 3. Southern blotting analysis. A: Images of southern blotting with probes RTT2, RTT3, and p(A)10. Lanes 1, 4, and 7 
are patient P3; Lanes 2, 5, and 8 are male control; and lanes 3, 6, and 9 are female control. B: Quantitation of each individual.  





Figure 4. Localization of the deletion junction in the female patient P3. Ten RD-PCR assays were developed in the flanking 
region of the MECP2 gene on X-chromosome.  Primers were designed according to the genomic sequence from NT_025965 
and the nucleotide positions are shown.  +/+ indicates two gene copies at the test locus, while +/- indicates only one copy.  The 
deletion junction was located within a region of 37kb upstream from 5’ end of exon 1 and 18kb downstream from 3’ end of 
exon 4 (3’UTR).  
 
RD-PCR was used for detection of heterozygous deletions and duplications in the MECP2 gene in RTT 
patients. One large deletion was identified in one of eight classical RTT patients without point mutations.  The 
prevalence of MECP2 gene heterozygous deletions detected by RD-PCR in our patients is 12.5% (1 out of 8), not 
significantly lower than the aggregate of the previous reports (12 out of 59) (Schollen et al., 2003; Erlandson et al., 
2003; Ariani et al., 2004; Laccone et al., 2004).  As illustrated by the ten additional dosage assays developed to 
characterize the deletion, rapid assay development and optimization are two important advantages of RD-PCR.  
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